15 completed, 2 recruiting, 2 terminated. 13 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 12, Terminated 1 |
| Phase 2 | 7 | Completed 4, Recruiting 2, Terminated 1 |
Follow prexasertib: new trials by email Literature Review of prexasertib trials Research Report on prexasertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC Gemcitabine, ACR-368 - Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 43 | 2024-09-25 | 2025-10-20 |
| A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma ACR-368, Gemcitabine, OncoSignature - Endometrial Adenocarcinoma | Phase 2 | Recruiting | Acrivon Therapeutics | 350 | 2022-08-29 | 2026-08-21 |
| A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma Prexasertib, Irinotecan - Desmoplastic Small Round Cell Tumor, Rhabdomyosarcoma | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 21 | 2019-09-17 | 2025-02-20 |
| Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors Prexasertib, Cyclophosphamide, Gemcitabine - Brain Tumor, Brain Tumor, Recurrent | Phase 1 | Completed | St. Jude Children's Research Hospital | 21 | 2019-08-08 | 2025-02-07 |
| Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial Prexasertib, Mitoxantrone, Etoposide - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Terminated | Dana-Farber Cancer Institute | 2 | 2019-01-18 | 2019-06-12 |
| A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors LY3300054, Prexasertib - Cancer | Phase 1 | Completed | Dana-Farber Cancer Institute | 17 | 2018-05-16 | 2021-04-15 |
| A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer Prexasertib - Ovarian Cancer | Phase 2 | Completed | Eli Lilly and Company | 172 | 2018-04-10 | 2022-08-19 |
| Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors Prexasertib, Olaparib - Solid Tumor | Phase 1 | Completed | Geoffrey Shapiro, MD, PhD | 29 | 2017-03-10 | 2021-09-02 |
| Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Laboratory Biomarker Analysis, Pharmacokinetic (PK) study, Prexasertib - Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm | Phase 1 | Completed | Children's Oncology Group | 30 | 2017-02-27 | 2023-12-20 |
| A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency LY2606368 - Advanced Cancers | Phase 2 | Completed | Dana-Farber Cancer Institute | 27 | 2016-10-12 | 2022-10-21 |
| A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer [¹⁴C]Prexasertib, Prexasertib - Advanced Cancer | Phase 1 | Completed | Eli Lilly and Company | 6 | 2016-09-22 | 2019-08-01 |
| A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer prexasertib, ralimetinib - Advanced Cancer, Metastatic Cancer | Phase 1 | Completed | Eli Lilly and Company | 9 | 2016-08-10 | 2018-12-14 |
| A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Prexasertib - Small Cell Lung Cancer | Phase 2 | Completed | Eli Lilly and Company | 133 | 2016-05-11 | 2020-03-17 |
| Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Cytarabine, Fludarabine Phosphate, Laboratory Biomarker Analysis - Chronic Myelomonocytic Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 15 | 2016-05-04 | 2023-10-04 |
| A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer Prexasertib, Cisplatin, Cetuximab - Head and Neck Neoplasms | Phase 1 | Completed | Eli Lilly and Company | 70 | 2016-02-24 | 2019-02-15 |
| A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers Prexasertib - Neoplasm | Phase 1 | Completed | Eli Lilly and Company | 12 | 2015-10-01 | 2017-05-22 |
| A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer LY2606368 - Ovarian Cancer, Breast Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 111 | 2015-01-20 | 2022-09-10 |
| A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer Prexasertib, Cisplatin, Cetuximab - Neoplasm Metastasis, Colorectal Neoplasms | Phase 1 | Completed | Eli Lilly and Company | 167 | 2014-06-18 | 2020-04-01 |
| A Phase 1 Study in Participants With Advanced Cancer Prexasertib - Advanced Cancer, Squamous Cell Carcinoma | Phase 1 | Completed | Eli Lilly and Company | 150 | 2010-02-01 | 2016-05-10 |
Neoplasms (4) · Neoplasm Metastasis (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Central Nervous System Neoplasms (2) · Colorectal Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Ovarian Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Anus Neoplasms (1) · Brain Neoplasms (1) · Carcinoma, Squamous Cell (1) · Desmoplastic Small Round Cell Tumor (1) · Endometrial Neoplasms (1) · Fanconi Anemia (1)
Eli Lilly and Company (8) · Dana-Farber Cancer Institute (3) · Acrivon Therapeutics (1) · Children's Oncology Group (1) · Geoffrey Shapiro, MD, PhD (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · St. Jude Children's Research Hospital (1)
United States (17) · France (3) · Germany (3) · Spain (3) · United Kingdom (3) · Italy (2) · South Korea (2) · Australia (1) · Belgium (1) · Greece (1) · Israel (1) · Japan (1) · Netherlands (1) · Turkey (Türkiye) (1) · Ukraine (1)
Christine Chung, MD (1) · Cynthia J Wetmore (1) · Emily Slotkin, MD (1) · Eric S Winer, MD (1) · Gautam Borthakur (1) · Geoffrey Shapiro, MD (1) · Geoffrey Shapiro, MD, PhD (1) · Geoffrey T Shapiro, MD (1) · Giles W. Robinson, MD (1) · Isabelle Ray-Coquard, MD (1) · Jung-Min Lee, M.D. (1) · Panagiotis Konstantinopoulos, MD (1)
PMID 34665631, PMID 27044938, PMID 28138028, PMID 29361470, PMID 29643063, PMID 32371584, PMID 33495309, PMID 33745032, PMID 33881209, PMID 34559360, PMID 34904813, PMID 36192237
2015 (4), 2017 (1), UM1CA097452 (1)